AI Visibility Scorecard
LGS DISCOVER Study
lgsdiscoverstudy.com · Healthcare
Borderline visible. AI bots can crawl LGS DISCOVER Study, but the structured-data signals are thin - you are at real risk of being skipped when buyers ask ChatGPT, Claude, or Perplexity for a recommendation.
AI engines read this profile 1 times
Claude
#659,740 of 923,557 in Healthcare for AI visibility
4
AEO Visibility
iBorderline · 4.2/10
0
Muse Index Score
iAI agent readiness
Not agent-ready · 0/100
0
AI Adoption
iNone detected · 0/100
About LGS DISCOVER Study
from our crawl and measurement
LGS DISCOVER Study is a business whose own site puts it this way: "SK Life Science - Medical Information provides the latest and up to date clinical information on our medicines." To AI engines like ChatGPT and Perplexity, though, it is barely visible: it scores 4.2 out of 10.
Our crawl found a readable heading structure. It is missing structured data describing the business, an llms.txt file and a sitemap.
The 6 signals AI reads
Strong · Good · Fair · Weak
Structured Data
Weak
Organization / LocalBusiness JSON-LD that AI can read.
Content Structure
Strong
Clear headings and answer-style content.
Entity Clarity
Weak
How clearly your brand identity reads to AI.
E-E-A-T Signals
Experience, Expertise, Authority, Trust
Fair
Experience, Expertise, Authority, Trust markers.
Technical AEO
Fair
robots.txt, llms.txt, and AI-bot crawl access.
AI Discoverability
Good
Sitemaps and entity links AI can follow.
Off-page authority
How the web signals your brand to AI
Backlinks
Weak
No inbound links found yet.
Domain Authority
Weak
Little domain authority yet.
Reference Presence
Weak
Not in AI knowledge graphs yet.
News & Press
Weak
No press coverage found yet.
Community
Weak
No community discussion yet.
Social Mentions
Weak
No social discussion found yet.
What this score means
Your AEO score measures whether AI search engines - ChatGPT, Claude, Perplexity, Gemini - can actually read your site and cite it in answers. Roughly two-thirds of sites are invisible to them. At 4.2/10, LGS DISCOVER Study is crawlable but under-signaled - fixable, and the signals above are where to start.
Frequently Asked Questions
What is the Purpose of the LGS DISCOVER Study?
The LGS DISCOVER study, also identified as the YKP509C003 study, is a clinical trial for pediatrics and adults with Lennox-Gastaut syndrome (LGS). LGS is a rare type of epilepsy that starts at an early age. People with LGS are resistant to multiple antiseizure medications (ASMs) and there is always a need for new medications.
How Does the Open-Label Extension Period and Expanded Access Study Work?
All participants will receive the study drug, carisbamate. During this time, dosage of carisbamate and/or antiseizure medications (ASMs) may be adjusted as needed. The maximum dose of carisbamate will be 300 mg twice a day or pediatric equivalent (based on patient weight). Additionally, once the 52-week open-label extension period is completed, the patient may have the opportunity to continue to receive carisbamate.
Is this your brand?
The exact fixes for LGS DISCOVER Study
Which AI engines already crawl you
Free AI bot monitoring: see every AI crawler that visits you
How to Get Your Brand Cited by ChatGPT, Gemini, and Claude: The Complete AEO Guide
The search landscape has fundamentally shifted. While Google still dominates, millions of users now ask questions to ChatGPT, Gemini, and Claude instead of typing into a search bar.
Continue reading in your free Engagemii portalFree signup unlocks the full article plus your personalized AEO fix list for LGS DISCOVER Study.
Source & Attribution
Scored by Engagemii on August 21, 2026. Methodology: engagemii.com/aeo/methodology
Source URL: https://engagemii.com/aeo/brands/lgsdiscoverstudy
Cite this score: Engagemii (2026). "AEO Score for LGS DISCOVER Study." Retrieved from https://engagemii.com/aeo/brands/lgsdiscoverstudy
Licensed under CC BY 4.0. You may reuse this data with attribution: a visible link to engagemii.com.
Powered by Engagemii - The Answer Engine Optimization (AEO) Platform